Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall …

Oct 31, 2024 · Travere Therapeutics (TVTX) reported $62.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 69.5%. EPS of -$0.70 for …

5%
OFF

Travere (TVTX) Q3 Earnings: How Key Metrics Compare To Wall …

2 weeks from now

Oct 31, 2024 · Travere Therapeutics (TVTX) reported $62.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 69.5%. EPS of -$0.70 for …

nasdaq.com

7%
OFF

Travere (TVTX) Q3 Earnings: How Key Metrics Compare To Wall …

2 weeks from now

Nov 7, 2023 · Travere Therapeutics (TVTX) reported $37.1 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 30.7%.

nasdaq.com

$48
OFF

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights ...

2 weeks from now

Nov 1, 2024 · Non-GAAP Adjusted R&D Expenses: $48.4 million for Q3 2024, compared to $53.8 million in Q3 2023. SG&A Expenses: $65.6 million for Q3 2024, down from $67.8 million in Q3 …

yahoo.com

$0.70
OFF

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue …

2 weeks from now

Oct 31, 2024 · Travere Therapeutics (TVTX) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.17 per share a year ago. …

yahoo.com

$0.70
OFF

Travere Therapeutics (TVTX) Earnings Date And Reports 2025

2 weeks from now

Travere Therapeutics announced Q3 2024 earnings on October 31, 2024, reporting an EPS of -$0.70, which topped the consensus estimate of -$0.71 by $0.01. Quarterly revenue rose …

marketbeat.com

$0.70
OFF

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue

2 weeks from now

Oct 31, 2024 · Travere Therapeutics (TVTX) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.17 per share a year ago. …

nasdaq.com

2%
OFF

Travere (TVTX) Q2 Earnings: How Key Metrics Compare To Wall …

2 weeks from now

Aug 4, 2023 · For the quarter ended June 2023, Travere Therapeutics (TVTX) reported revenue of $59.7 million, up 10.2% over the same period last year. EPS came in at -$1.13, compared …

nasdaq.com

40%
OFF

Travere's FILSPARI Drives $50M Q4 Sales, European Expansion …

2 weeks from now

2 days ago · The Q4 2024 performance shows strong commercial momentum for FILSPARI, with 693 new patient start forms and $50 million in net product sales, marking a 40% sequential …

stocktitan.net